Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
Publication stageIn Press Journal Pre-Proof
All authors report no conflict of interest and no financial disclosures.
Trial registration number: NCT04685694 www.clinicalTrials.gov
Trial registration date: October 1, 2020
Medical treatment with misoprostol has no clinically meaningful advantage over expectant management for women diagnosed with retained products of conception following medical termination of pregnancy.
AJOG at a Glance
• Why was this study conducted?
Expectant management and medical treatment with misoprostol are widely accepted alternative treatments for retained products of conception (RPOC). This study aimed to compare the safety and efficacy of medical treatment with misoprostol with expectant management in women with suspected RPOC following first trimester medical termination of pregnancy.
• What are the key findings?
There is no clinically meaningful advantage of medical treatment with misoprostol over expectant management after first trimester medical termination of pregnancy in women with RPOC.
• What does this study add to what is already known?
This is the first prospective randomized study to provide evidenced-based clinical documentation on the efficacy of misoprostol in the management of RPOC after first trimester medical termination of pregnancy.